Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s ...

Most people receive Keytruda infusions for up to 2 years. But in some cases, treatment may last longer if there’s evidence that the drug is still effective and the side effects are minimal.

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

The list price of Keytruda for an average treatment duration is around £29,000, which NICE originally ruled made it not cost effective. NICE changed its mind in this second draft guidance ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Objective response rate was higher in the Lenvima plus Keytruda arm (47%) compared to the placebo arm (33%). Severe treatment-related side effects were more common in the combination therapy group, ...

Keytruda (pembrolizumab ... allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe ...

Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant ... The issue with TKIs is that their effects tend to be short-lived, as tumours develop random mutations in target ...

Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA ® or OPDIVO ... microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA ...

The FDA approved Padcev and Keytruda for advanced bladder cancer in December 2023, following accelerated approval for cisplatin-ineligible patients. Both treatments have lower odds of high-grade side ...